查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1193120

藥物發現外包市場：按工作流程、治療領域、藥物類型、最終用戶分類：2021-2031 年全球機會分析和行業預測

Drug Discovery Outsourcing Market By Workflow, By Therapeutic area, By Drug Type, By End User : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 251 Pages | 商品交期: 2-3個工作天內

價格

全球藥物發現外包市場預計2021年將達到36億美元，2031年將達到74億美元，2022年至2031年將以7.5%的複合年增長率增長。

藥物發現外包被定義為各種公司通過將部分工作轉移給外部供應商來降低藥物開發成本的技術。 外包在各個領域進行，從藥物發現到商業化。 通過外包給專門從事藥物商業化的第三方，您可以最大限度地提高藥物的價值主張。 在藥理學、製藥學和生物技術等各個領域發現新藥和藥物的過程。

此外，合同研究組織 (CRO) 還為製藥和生物技術公司提供各種藥物發現研究服務。 製藥公司現在將研發活動外包給私人合同研究組織 (CRO) 和學術研究機構，以減少藥物開發時間和成本。

癌症、心血管疾病、糖尿病和高血壓等慢性病的增加、藥物發現研發活動的增加以及靶向藥物治療需求的激增是推動藥物發現外包市場增長的主要因素。 例如，根據 IQVIA 2022 年 6 月的一份報告，2016 年腫瘤藥物開發的試驗數量達到 56% 的歷史新高。 2021年全球首次上市腫瘤領域新活性物質30個，創歷史新高，自2012年以來共上市159個。 因此，越來越多的研究活動將增加進行臨床試驗以在市場上推出新分子的需求，增加對外包服務提供商的需求，從而推動市場的增長。

此外，製藥公司越來越多地採用外包服務以及越來越多的主要參與者作為新藥發佈的 CRO 預計也將推動市場增長。 例如，美國和歐洲有超過 1,000 家 CRO。 前 10 名公司約佔行業收入的 40%。 然而，CRO將重點放在藥物研發和臨床試驗支持上，可以有效加速新藥上市。

然而，不僅成本高，藥物失敗的風險高，而且熟練專業人員的短缺阻礙了市場的增長。 另一方面，新興國家癌症、遺傳病和慢性病發病率的增加、老年人口的增加、有利的監管環境以及具有高質量數據的低成本熟練勞動力的可用性將有助於預測期內的市場增長。提供有利可圖的機會

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章藥物發現外包市場：按工作流程

  • 概覽
    • 市場規模和預測
  • 目標識別和篩選
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 目標驗證和功能信息學
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 潛在客戶識別和候選人優化
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 臨床前開發
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章藥物發現外包市場：按治療領域分類

  • 概覽
    • 市場規模和預測
  • 呼吸系統
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 感染
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 腫瘤學
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 免疫學
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 血液學
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 循環區
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 中樞神經系統 (CNS)
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 消化系統
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章藥物發現外包市場：按藥物類型分類

  • 概覽
    • 市場規模和預測
  • 小分子藥物
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 大分子
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 7 章藥物發現外包市場：最終用戶

  • 概覽
    • 市場規模和預測
  • 製藥公司、生物技術公司
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 學術機構
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 8 章藥物發現外包市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按工作流程
    • 北美市場規模和預測：按治療領域
    • 北美市場規模和預測：按藥物類型
    • 北美市場規模和預測：按最終用戶分類
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按工作流程
    • 歐洲市場規模和預測：按治療領域
    • 歐洲市場規模和預測：按藥物類型
    • 歐洲市場規模和預測：按最終用戶分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太市場規模和預測：按工作流程
    • 亞太市場規模和預測：按治療領域
    • 亞太市場規模和預測：按藥物類型
    • 亞太市場規模和預測：按最終用戶分類
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機遇
    • LAMEA 市場規模和預測：按工作流程
    • LAMEA 市場規模和預測：按治療領域
    • LAMEA 市場規模和預測：按藥物類型
    • LAMEA 市場規模和預測：按最終用戶分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其餘部分

第九章商業條件

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第十章公司簡介

  • . Charles River Laboratories,
  • Curia Global Inc
  • Dr. Reddy's Laboratories
  • Dalton Pharma Service
  • Discover X Corporation
  • Laboratory Corporation of America Holdings
  • Merck & Co
  • Syngene International Ltd
  • Thermo Fisher Scientific, Inc.
  • TCG Life Science Pvt. Ltd
Product Code: A14914

The global Drug Discovery Outsourcing Market Size was valued at $3.6 billion in 2021 and is projected to reach $7.4 billion by 2031, growing at a CAGR of 7.5% from 2022 to 2031.. Drug discovery outsourcing is defined as a practice that is used by different companies to reduce the cost of drug development by transferring portions of work to outside suppliers. Outsourced activities can be carried out in various fields, right from drug discovery to the manufacturing of products. Outsourcing drug commercialization to a third-party service provider specializing in drug commercialization helps to ensure the maximization of a drug product's value proposition.  It is a procedure that is used to find new medicines or drugs in different fields such as pharmacology, pharmaceuticals, and biotechnology.

Moreover, drug discovery contract research organizations (CROs) are engaged in offering a range of research services on a contract basis to pharmaceutical and biotechnology companies for drug discovery. Pharmaceutical companies are now outsourcing their R&D activities to private contract research organizations (CROs) and academic research institutions to reduce drug development time and cost.

The key factors that drive the growth of the market are the rise in the prevalence of chronic diseases such as cancer, cardiovascular disease, diabetes, and high blood pressure; the increase in R&D activities for drug discovery, and the surge in demand for target drug therapy are the major factors that drive the growth of the drug discovery outsourcing market. For instance, according to the report published by IQVIA in June 2022, the number of trials in oncology drug development reached a historic high of 56% in 2016.  A record 30 oncology novel active substances were initially launched globally in 2021, and a total of 159 have been launched since 2012. Thus, the rise in the number of research activities increases the demand for performing clinical trials to launch new molecules in the market, which increases the demand for outsourcing service providers and hence boosts the growth of the market.

Furthermore, rise in the adoption of outsourcing services by pharmaceutical companies and the increase in the number of key players as CROs for the launch of novel drug therapies are anticipated to fuel the growth of the market. For instance, there are more than 1,000 CROs in the U.S. and Europe. The top 10 accounts for approximately 40% of industry sales. However, CROs have been focused on drug development and clinical trial support, where they can effectively speed the launch of a new drug in the market.

However, the high cost as well as the high risk of drug failure, along with the lack of skilled professionals, hamper the market's growth. Conversely, rising cases of cancer, genetic disease, & chronic disease; large geriatric population; a favorable regulatory environment; and the availability of low-cost skilled manpower with high-quality data in the developing countries are expected to provide a lucrative opportunity for the growth of the market during the forecast period. 

The drug discovery outsourcing market is segmented on the basis of workflow, therapeutic area, drug type, end user, and region. By workflow, it is fragmented into target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and others. By therapeutic area, it is classified into the respiratory system, infectious disease, oncology, immunology, hematology, cardiovascular, central nervous system, gastrointestinal, and others. By drug type, it is bifurcated into small molecules and large molecules. By end user, the market is categorized into pharmaceutical & biotechnology companies, academic institutes, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for a majority of the drug discovery outsourcing market share in 2021 and is anticipated to remain dominant during the forecast period. The drug discovery outsourcing market is mainly driven by the presence of well-established research facilities and a high prevalence rate of cancer & chronic diseases. Moreover, the availability of technologically advanced medical devices and the rise in the demand for target drug therapy techniques to cure cancer are contributing to the growth of the market in this region. Furthermore, an increasing number of key players involved in R&D activities for the discovery of novel drugs is expected to fuel market growth.

Asia-Pacific is expected to register the fastest CAGR during the forecast period. This is due to the availability of low-cost skilled manpower and high-quality clinical trial data and constantly improving healthcare infrastructure. In addition, the rapidly growing population, rising incidence of cancer & chronic disease, and improvement in the quality of healthcare facilities are set to drive the market in Asia-Pacific. This helps several key market players to invest in Asia-Pacific countries, which in turn, is further expected to contribute to the growth of the market.

The key players that operate in the drug discovery outsourcing market are Curia Global Inc, Charles River Laboratories Inc, Dr. Reddy's Laboratories, Discover X Corporation, Dalton Pharma Service, Laboratory Corporation of America Holdings, Merck & Co, Syngene International Ltd, TCG Life Science Pvt. Ltd, and Thermo Fisher Scientific.

Key Benefits For Stakeholders 

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the drug discovery outsourcing market analysis from 2021 to 2031 to identify the prevailing drug discovery outsourcing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the drug discovery outsourcing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes an analysis of the regional as well as global drug discovery outsourcing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Workflow

  • Target Validation and Functional Informatics
  • Lead Identification and Candidate Optimization
  • Preclinical Development
  • Others
  • Target Identification and Screening

By Therapeutic area

  • Cardiovascular
  • Central Nervous System (CNS)
  • Gastrointestinal
  • Others
  • Hematology
  • Respiratory system
  • Infectious disease
  • Oncology
  • Immunology

By Drug Type

  • Small Molecules
  • Large Molecules

By End User

  • Pharmaceutical and Biotechnology companies
  • Academic Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • . Charles River Laboratories,
    • Curia Global Inc
    • Dr. Reddy's Laboratories
    • Dalton Pharma Service
    • Discover X Corporation
    • Laboratory Corporation of America Holdings
    • Merck & Co
    • Syngene International Ltd
    • Thermo Fisher Scientific, Inc.
    • TCG Life Science Pvt. Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Target Identification and Screening
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Target Validation and Functional Informatics
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Lead Identification and Candidate Optimization
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country
  • 4.5 Preclinical Development
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market share analysis by country
  • 4.6 Others
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market share analysis by country

CHAPTER 5: DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Respiratory system
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Infectious disease
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country
  • 5.4 Oncology
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market share analysis by country
  • 5.5 Immunology
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market share analysis by country
  • 5.6 Hematology
    • 5.6.1 Key market trends, growth factors and opportunities
    • 5.6.2 Market size and forecast, by region
    • 5.6.3 Market share analysis by country
  • 5.7 Cardiovascular
    • 5.7.1 Key market trends, growth factors and opportunities
    • 5.7.2 Market size and forecast, by region
    • 5.7.3 Market share analysis by country
  • 5.8 Central Nervous System (CNS)
    • 5.8.1 Key market trends, growth factors and opportunities
    • 5.8.2 Market size and forecast, by region
    • 5.8.3 Market share analysis by country
  • 5.9 Gastrointestinal
    • 5.9.1 Key market trends, growth factors and opportunities
    • 5.9.2 Market size and forecast, by region
    • 5.9.3 Market share analysis by country
  • 6.0 Others
    • 6.0.1 Key market trends, growth factors and opportunities
    • 6.0.2 Market size and forecast, by region
    • 6.0.3 Market share analysis by country

CHAPTER 6: DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Small Molecules
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Large Molecules
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country

CHAPTER 7: DRUG DISCOVERY OUTSOURCING MARKET, BY END USER

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 Pharmaceutical and Biotechnology companies
    • 7.2.1 Key market trends, growth factors and opportunities
    • 7.2.2 Market size and forecast, by region
    • 7.2.3 Market share analysis by country
  • 7.3 Academic Institutes
    • 7.3.1 Key market trends, growth factors and opportunities
    • 7.3.2 Market size and forecast, by region
    • 7.3.3 Market share analysis by country
  • 7.4 Others
    • 7.4.1 Key market trends, growth factors and opportunities
    • 7.4.2 Market size and forecast, by region
    • 7.4.3 Market share analysis by country

CHAPTER 8: DRUG DISCOVERY OUTSOURCING MARKET, BY REGION

  • 8.1 Overview
    • 8.1.1 Market size and forecast
  • 8.2 North America
    • 8.2.1 Key trends and opportunities
    • 8.2.2 North America Market size and forecast, by Workflow
    • 8.2.3 North America Market size and forecast, by Therapeutic area
    • 8.2.4 North America Market size and forecast, by Drug Type
    • 8.2.5 North America Market size and forecast, by End User
    • 8.2.6 North America Market size and forecast, by country
      • 8.2.6.1 U.S.
      • 8.2.6.1.1 Key market trends, growth factors and opportunities
      • 8.2.6.1.2 Market size and forecast, by Workflow
      • 8.2.6.1.3 Market size and forecast, by Therapeutic area
      • 8.2.6.1.4 Market size and forecast, by Drug Type
      • 8.2.6.1.5 Market size and forecast, by End User
      • 8.2.6.2 Canada
      • 8.2.6.2.1 Key market trends, growth factors and opportunities
      • 8.2.6.2.2 Market size and forecast, by Workflow
      • 8.2.6.2.3 Market size and forecast, by Therapeutic area
      • 8.2.6.2.4 Market size and forecast, by Drug Type
      • 8.2.6.2.5 Market size and forecast, by End User
      • 8.2.6.3 Mexico
      • 8.2.6.3.1 Key market trends, growth factors and opportunities
      • 8.2.6.3.2 Market size and forecast, by Workflow
      • 8.2.6.3.3 Market size and forecast, by Therapeutic area
      • 8.2.6.3.4 Market size and forecast, by Drug Type
      • 8.2.6.3.5 Market size and forecast, by End User
  • 8.3 Europe
    • 8.3.1 Key trends and opportunities
    • 8.3.2 Europe Market size and forecast, by Workflow
    • 8.3.3 Europe Market size and forecast, by Therapeutic area
    • 8.3.4 Europe Market size and forecast, by Drug Type
    • 8.3.5 Europe Market size and forecast, by End User
    • 8.3.6 Europe Market size and forecast, by country
      • 8.3.6.1 Germany
      • 8.3.6.1.1 Key market trends, growth factors and opportunities
      • 8.3.6.1.2 Market size and forecast, by Workflow
      • 8.3.6.1.3 Market size and forecast, by Therapeutic area
      • 8.3.6.1.4 Market size and forecast, by Drug Type
      • 8.3.6.1.5 Market size and forecast, by End User
      • 8.3.6.2 France
      • 8.3.6.2.1 Key market trends, growth factors and opportunities
      • 8.3.6.2.2 Market size and forecast, by Workflow
      • 8.3.6.2.3 Market size and forecast, by Therapeutic area
      • 8.3.6.2.4 Market size and forecast, by Drug Type
      • 8.3.6.2.5 Market size and forecast, by End User
      • 8.3.6.3 UK
      • 8.3.6.3.1 Key market trends, growth factors and opportunities
      • 8.3.6.3.2 Market size and forecast, by Workflow
      • 8.3.6.3.3 Market size and forecast, by Therapeutic area
      • 8.3.6.3.4 Market size and forecast, by Drug Type
      • 8.3.6.3.5 Market size and forecast, by End User
      • 8.3.6.4 Italy
      • 8.3.6.4.1 Key market trends, growth factors and opportunities
      • 8.3.6.4.2 Market size and forecast, by Workflow
      • 8.3.6.4.3 Market size and forecast, by Therapeutic area
      • 8.3.6.4.4 Market size and forecast, by Drug Type
      • 8.3.6.4.5 Market size and forecast, by End User
      • 8.3.6.5 Spain
      • 8.3.6.5.1 Key market trends, growth factors and opportunities
      • 8.3.6.5.2 Market size and forecast, by Workflow
      • 8.3.6.5.3 Market size and forecast, by Therapeutic area
      • 8.3.6.5.4 Market size and forecast, by Drug Type
      • 8.3.6.5.5 Market size and forecast, by End User
      • 8.3.6.6 Rest of Europe
      • 8.3.6.6.1 Key market trends, growth factors and opportunities
      • 8.3.6.6.2 Market size and forecast, by Workflow
      • 8.3.6.6.3 Market size and forecast, by Therapeutic area
      • 8.3.6.6.4 Market size and forecast, by Drug Type
      • 8.3.6.6.5 Market size and forecast, by End User
  • 8.4 Asia-Pacific
    • 8.4.1 Key trends and opportunities
    • 8.4.2 Asia-Pacific Market size and forecast, by Workflow
    • 8.4.3 Asia-Pacific Market size and forecast, by Therapeutic area
    • 8.4.4 Asia-Pacific Market size and forecast, by Drug Type
    • 8.4.5 Asia-Pacific Market size and forecast, by End User
    • 8.4.6 Asia-Pacific Market size and forecast, by country
      • 8.4.6.1 Japan
      • 8.4.6.1.1 Key market trends, growth factors and opportunities
      • 8.4.6.1.2 Market size and forecast, by Workflow
      • 8.4.6.1.3 Market size and forecast, by Therapeutic area
      • 8.4.6.1.4 Market size and forecast, by Drug Type
      • 8.4.6.1.5 Market size and forecast, by End User
      • 8.4.6.2 China
      • 8.4.6.2.1 Key market trends, growth factors and opportunities
      • 8.4.6.2.2 Market size and forecast, by Workflow
      • 8.4.6.2.3 Market size and forecast, by Therapeutic area
      • 8.4.6.2.4 Market size and forecast, by Drug Type
      • 8.4.6.2.5 Market size and forecast, by End User
      • 8.4.6.3 Australia
      • 8.4.6.3.1 Key market trends, growth factors and opportunities
      • 8.4.6.3.2 Market size and forecast, by Workflow
      • 8.4.6.3.3 Market size and forecast, by Therapeutic area
      • 8.4.6.3.4 Market size and forecast, by Drug Type
      • 8.4.6.3.5 Market size and forecast, by End User
      • 8.4.6.4 India
      • 8.4.6.4.1 Key market trends, growth factors and opportunities
      • 8.4.6.4.2 Market size and forecast, by Workflow
      • 8.4.6.4.3 Market size and forecast, by Therapeutic area
      • 8.4.6.4.4 Market size and forecast, by Drug Type
      • 8.4.6.4.5 Market size and forecast, by End User
      • 8.4.6.5 South Korea
      • 8.4.6.5.1 Key market trends, growth factors and opportunities
      • 8.4.6.5.2 Market size and forecast, by Workflow
      • 8.4.6.5.3 Market size and forecast, by Therapeutic area
      • 8.4.6.5.4 Market size and forecast, by Drug Type
      • 8.4.6.5.5 Market size and forecast, by End User
      • 8.4.6.6 Rest of Asia-Pacific
      • 8.4.6.6.1 Key market trends, growth factors and opportunities
      • 8.4.6.6.2 Market size and forecast, by Workflow
      • 8.4.6.6.3 Market size and forecast, by Therapeutic area
      • 8.4.6.6.4 Market size and forecast, by Drug Type
      • 8.4.6.6.5 Market size and forecast, by End User
  • 8.5 LAMEA
    • 8.5.1 Key trends and opportunities
    • 8.5.2 LAMEA Market size and forecast, by Workflow
    • 8.5.3 LAMEA Market size and forecast, by Therapeutic area
    • 8.5.4 LAMEA Market size and forecast, by Drug Type
    • 8.5.5 LAMEA Market size and forecast, by End User
    • 8.5.6 LAMEA Market size and forecast, by country
      • 8.5.6.1 Brazil
      • 8.5.6.1.1 Key market trends, growth factors and opportunities
      • 8.5.6.1.2 Market size and forecast, by Workflow
      • 8.5.6.1.3 Market size and forecast, by Therapeutic area
      • 8.5.6.1.4 Market size and forecast, by Drug Type
      • 8.5.6.1.5 Market size and forecast, by End User
      • 8.5.6.2 Saudi Arabia
      • 8.5.6.2.1 Key market trends, growth factors and opportunities
      • 8.5.6.2.2 Market size and forecast, by Workflow
      • 8.5.6.2.3 Market size and forecast, by Therapeutic area
      • 8.5.6.2.4 Market size and forecast, by Drug Type
      • 8.5.6.2.5 Market size and forecast, by End User
      • 8.5.6.3 South Africa
      • 8.5.6.3.1 Key market trends, growth factors and opportunities
      • 8.5.6.3.2 Market size and forecast, by Workflow
      • 8.5.6.3.3 Market size and forecast, by Therapeutic area
      • 8.5.6.3.4 Market size and forecast, by Drug Type
      • 8.5.6.3.5 Market size and forecast, by End User
      • 8.5.6.4 Rest of LAMEA
      • 8.5.6.4.1 Key market trends, growth factors and opportunities
      • 8.5.6.4.2 Market size and forecast, by Workflow
      • 8.5.6.4.3 Market size and forecast, by Therapeutic area
      • 8.5.6.4.4 Market size and forecast, by Drug Type
      • 8.5.6.4.5 Market size and forecast, by End User

CHAPTER 9: COMPANY LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Key developments

CHAPTER 10: COMPANY PROFILES

  • 10.1 . Charles River Laboratories,
    • 10.1.1 Company overview
    • 10.1.2 Company snapshot
    • 10.1.3 Operating business segments
    • 10.1.4 Product portfolio
    • 10.1.5 Business performance
    • 10.1.6 Key strategic moves and developments
  • 10.2 Curia Global Inc
    • 10.2.1 Company overview
    • 10.2.2 Company snapshot
    • 10.2.3 Operating business segments
    • 10.2.4 Product portfolio
    • 10.2.5 Business performance
    • 10.2.6 Key strategic moves and developments
  • 10.3 Dr. Reddy's Laboratories
    • 10.3.1 Company overview
    • 10.3.2 Company snapshot
    • 10.3.3 Operating business segments
    • 10.3.4 Product portfolio
    • 10.3.5 Business performance
    • 10.3.6 Key strategic moves and developments
  • 10.4 Dalton Pharma Service
    • 10.4.1 Company overview
    • 10.4.2 Company snapshot
    • 10.4.3 Operating business segments
    • 10.4.4 Product portfolio
    • 10.4.5 Business performance
    • 10.4.6 Key strategic moves and developments
  • 10.5 Discover X Corporation
    • 10.5.1 Company overview
    • 10.5.2 Company snapshot
    • 10.5.3 Operating business segments
    • 10.5.4 Product portfolio
    • 10.5.5 Business performance
    • 10.5.6 Key strategic moves and developments
  • 10.6 Laboratory Corporation of America Holdings
    • 10.6.1 Company overview
    • 10.6.2 Company snapshot
    • 10.6.3 Operating business segments
    • 10.6.4 Product portfolio
    • 10.6.5 Business performance
    • 10.6.6 Key strategic moves and developments
  • 10.7 Merck & Co
    • 10.7.1 Company overview
    • 10.7.2 Company snapshot
    • 10.7.3 Operating business segments
    • 10.7.4 Product portfolio
    • 10.7.5 Business performance
    • 10.7.6 Key strategic moves and developments
  • 10.8 Syngene International Ltd
    • 10.8.1 Company overview
    • 10.8.2 Company snapshot
    • 10.8.3 Operating business segments
    • 10.8.4 Product portfolio
    • 10.8.5 Business performance
    • 10.8.6 Key strategic moves and developments
  • 10.9 Thermo Fisher Scientific, Inc.
    • 10.9.1 Company overview
    • 10.9.2 Company snapshot
    • 10.9.3 Operating business segments
    • 10.9.4 Product portfolio
    • 10.9.5 Business performance
    • 10.9.6 Key strategic moves and developments
  • 10.10 TCG Life Science Pvt. Ltd
    • 10.10.1 Company overview
    • 10.10.2 Company snapshot
    • 10.10.3 Operating business segments
    • 10.10.4 Product portfolio
    • 10.10.5 Business performance
    • 10.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET IDENTIFICATION AND SCREENING, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET IDENTIFICATION AND SCREENING, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET VALIDATION AND FUNCTIONAL INFORMATICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. DRUG DISCOVERY OUTSOURCING MARKET FOR TARGET VALIDATION AND FUNCTIONAL INFORMATICS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. DRUG DISCOVERY OUTSOURCING MARKET FOR LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. DRUG DISCOVERY OUTSOURCING MARKET FOR LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. DRUG DISCOVERY OUTSOURCING MARKET FOR PRECLINICAL DEVELOPMENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. DRUG DISCOVERY OUTSOURCING MARKET FOR PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. DRUG DISCOVERY OUTSOURCING MARKET FOR RESPIRATORY SYSTEM, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. DRUG DISCOVERY OUTSOURCING MARKET FOR RESPIRATORY SYSTEM, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. DRUG DISCOVERY OUTSOURCING MARKET FOR INFECTIOUS DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. DRUG DISCOVERY OUTSOURCING MARKET FOR INFECTIOUS DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. DRUG DISCOVERY OUTSOURCING MARKET FOR ONCOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. DRUG DISCOVERY OUTSOURCING MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. DRUG DISCOVERY OUTSOURCING MARKET FOR IMMUNOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. DRUG DISCOVERY OUTSOURCING MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. DRUG DISCOVERY OUTSOURCING MARKET FOR HEMATOLOGY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. DRUG DISCOVERY OUTSOURCING MARKET FOR HEMATOLOGY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. DRUG DISCOVERY OUTSOURCING MARKET FOR CARDIOVASCULAR, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. DRUG DISCOVERY OUTSOURCING MARKET FOR CARDIOVASCULAR, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. DRUG DISCOVERY OUTSOURCING MARKET FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. DRUG DISCOVERY OUTSOURCING MARKET FOR CENTRAL NERVOUS SYSTEM (CNS), BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. DRUG DISCOVERY OUTSOURCING MARKET FOR GASTROINTESTINAL, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. DRUG DISCOVERY OUTSOURCING MARKET FOR GASTROINTESTINAL, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. DRUG DISCOVERY OUTSOURCING MARKET FOR SMALL MOLECULES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. DRUG DISCOVERY OUTSOURCING MARKET FOR SMALL MOLECULES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. DRUG DISCOVERY OUTSOURCING MARKET FOR LARGE MOLECULES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. DRUG DISCOVERY OUTSOURCING MARKET FOR LARGE MOLECULES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. GLOBAL DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. DRUG DISCOVERY OUTSOURCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. DRUG DISCOVERY OUTSOURCING MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. DRUG DISCOVERY OUTSOURCING MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. DRUG DISCOVERY OUTSOURCING MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. DRUG DISCOVERY OUTSOURCING MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. DRUG DISCOVERY OUTSOURCING MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. NORTH AMERICA DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. U.S. DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. CANADA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. MEXICO DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. GERMANY DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. FRANCE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. UK DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. UK DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. UK DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. UK DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. ITALY DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. SPAIN DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94. ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 95. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 96. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 97. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 98. JAPAN DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 99. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 100. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 101. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 102. CHINA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 103. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 104. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 105. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 106. AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 107. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 108. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 109. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 110. INDIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 111. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 112. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 113. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 114. SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 115. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 116. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 117. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 118. REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 119. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 120. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 121. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 122. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 123. LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 124. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 125. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 126. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 127. BRAZIL DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 128. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 129. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 130. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 131. SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 132. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 133. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 134. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 135. SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 136. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY WORKFLOW, 2021-2031 (REVENUE, $MILLION)
  • TABLE 137. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY THERAPEUTIC AREA, 2021-2031 (REVENUE, $MILLION)
  • TABLE 138. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 139. REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 140.. CHARLES RIVER LABORATORIES,: COMPANY SNAPSHOT
  • TABLE 141.. CHARLES RIVER LABORATORIES,: OPERATING SEGMENTS
  • TABLE 142.. CHARLES RIVER LABORATORIES,: PRODUCT PORTFOLIO
  • TABLE 143.. CHARLES RIVER LABORATORIES,: NET SALES
  • TABLE 144.. CHARLES RIVER LABORATORIES,: KEY STRATERGIES
  • TABLE 145.CURIA GLOBAL INC: COMPANY SNAPSHOT
  • TABLE 146.CURIA GLOBAL INC: OPERATING SEGMENTS
  • TABLE 147.CURIA GLOBAL INC: PRODUCT PORTFOLIO
  • TABLE 148.CURIA GLOBAL INC: NET SALES
  • TABLE 149.CURIA GLOBAL INC: KEY STRATERGIES
  • TABLE 150.DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT
  • TABLE 151.DR. REDDY'S LABORATORIES: OPERATING SEGMENTS
  • TABLE 152.DR. REDDY'S LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 153.DR. REDDY'S LABORATORIES: NET SALES
  • TABLE 154.DR. REDDY'S LABORATORIES: KEY STRATERGIES
  • TABLE 155.DALTON PHARMA SERVICE: COMPANY SNAPSHOT
  • TABLE 156.DALTON PHARMA SERVICE: OPERATING SEGMENTS
  • TABLE 157.DALTON PHARMA SERVICE: PRODUCT PORTFOLIO
  • TABLE 158.DALTON PHARMA SERVICE: NET SALES
  • TABLE 159.DALTON PHARMA SERVICE: KEY STRATERGIES
  • TABLE 160.DISCOVER X CORPORATION: COMPANY SNAPSHOT
  • TABLE 161.DISCOVER X CORPORATION: OPERATING SEGMENTS
  • TABLE 162.DISCOVER X CORPORATION: PRODUCT PORTFOLIO
  • TABLE 163.DISCOVER X CORPORATION: NET SALES
  • TABLE 164.DISCOVER X CORPORATION: KEY STRATERGIES
  • TABLE 165.LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
  • TABLE 166.LABORATORY CORPORATION OF AMERICA HOLDINGS: OPERATING SEGMENTS
  • TABLE 167.LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT PORTFOLIO
  • TABLE 168.LABORATORY CORPORATION OF AMERICA HOLDINGS: NET SALES
  • TABLE 169.LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY STRATERGIES
  • TABLE 170.MERCK & CO: COMPANY SNAPSHOT
  • TABLE 171.MERCK & CO: OPERATING SEGMENTS
  • TABLE 172.MERCK & CO: PRODUCT PORTFOLIO
  • TABLE 173.MERCK & CO: NET SALES
  • TABLE 174.MERCK & CO: KEY STRATERGIES
  • TABLE 175.SYNGENE INTERNATIONAL LTD: COMPANY SNAPSHOT
  • TABLE 176.SYNGENE INTERNATIONAL LTD: OPERATING SEGMENTS
  • TABLE 177.SYNGENE INTERNATIONAL LTD: PRODUCT PORTFOLIO
  • TABLE 178.SYNGENE INTERNATIONAL LTD: NET SALES
  • TABLE 179.SYNGENE INTERNATIONAL LTD: KEY STRATERGIES
  • TABLE 180.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 181.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 182.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 183.THERMO FISHER SCIENTIFIC, INC.: NET SALES
  • TABLE 184.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
  • TABLE 185.TCG LIFE SCIENCE PVT. LTD: COMPANY SNAPSHOT
  • TABLE 186.TCG LIFE SCIENCE PVT. LTD: OPERATING SEGMENTS
  • TABLE 187.TCG LIFE SCIENCE PVT. LTD: PRODUCT PORTFOLIO
  • TABLE 188.TCG LIFE SCIENCE PVT. LTD: NET SALES
  • TABLE 189.TCG LIFE SCIENCE PVT. LTD: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.DRUG DISCOVERY OUTSOURCING MARKET SEGMENTATION
  • FIGURE 2.DRUG DISCOVERY OUTSOURCING MARKET,2021-2031
  • FIGURE 3.DRUG DISCOVERY OUTSOURCING MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.DRUG DISCOVERY OUTSOURCING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.DRUG DISCOVERY OUTSOURCING MARKET,BY WORKFLOW,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF TARGET IDENTIFICATION AND SCREENING DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TARGET VALIDATION AND FUNCTIONAL INFORMATICS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF LEAD IDENTIFICATION AND CANDIDATE OPTIMIZATION DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF PRECLINICAL DEVELOPMENT DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 18.DRUG DISCOVERY OUTSOURCING MARKET,BY THERAPEUTIC AREA,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF RESPIRATORY SYSTEM DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF INFECTIOUS DISEASE DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ONCOLOGY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF IMMUNOLOGY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HEMATOLOGY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF CARDIOVASCULAR DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF CENTRAL NERVOUS SYSTEM (CNS) DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 26.COMPARATIVE SHARE ANALYSIS OF GASTROINTESTINAL DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 27.COMPARATIVE SHARE ANALYSIS OF OTHERS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 28.DRUG DISCOVERY OUTSOURCING MARKET,BY DRUG TYPE,2021(%)
  • FIGURE 29.COMPARATIVE SHARE ANALYSIS OF SMALL MOLECULES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 30.COMPARATIVE SHARE ANALYSIS OF LARGE MOLECULES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 31.DRUG DISCOVERY OUTSOURCING MARKET,BY END USER,2021(%)
  • FIGURE 32.COMPARATIVE SHARE ANALYSIS OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 33.COMPARATIVE SHARE ANALYSIS OF ACADEMIC INSTITUTES DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 34.COMPARATIVE SHARE ANALYSIS OF OTHERS DRUG DISCOVERY OUTSOURCING MARKET,2021-2031(%)
  • FIGURE 35.DRUG DISCOVERY OUTSOURCING MARKET BY REGION,2021
  • FIGURE 36.U.S. DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 37.CANADA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 38.MEXICO DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 39.GERMANY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 40.FRANCE DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 41.UK DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 42.ITALY DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 43.SPAIN DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 44.REST OF EUROPE DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 45.JAPAN DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 46.CHINA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 47.AUSTRALIA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 48.INDIA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 49.SOUTH KOREA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 50.REST OF ASIA-PACIFIC DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 51.BRAZIL DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 52.SAUDI ARABIA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 53.SOUTH AFRICA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 54.REST OF LAMEA DRUG DISCOVERY OUTSOURCING MARKET,2021-2031($MILLION)
  • FIGURE 55. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 56. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 57. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 58.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 59.COMPETITIVE DASHBOARD
  • FIGURE 60.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 61.. CHARLES RIVER LABORATORIES,.: NET SALES ($MILLION)
  • FIGURE 62.CURIA GLOBAL INC.: NET SALES ($MILLION)
  • FIGURE 63.DR. REDDY'S LABORATORIES.: NET SALES ($MILLION)
  • FIGURE 64.DALTON PHARMA SERVICE.: NET SALES ($MILLION)
  • FIGURE 65.DISCOVER X CORPORATION.: NET SALES ($MILLION)
  • FIGURE 66.LABORATORY CORPORATION OF AMERICA HOLDINGS.: NET SALES ($MILLION)
  • FIGURE 67.MERCK & CO.: NET SALES ($MILLION)
  • FIGURE 68.SYNGENE INTERNATIONAL LTD.: NET SALES ($MILLION)
  • FIGURE 69.THERMO FISHER SCIENTIFIC, INC..: NET SALES ($MILLION)
  • FIGURE 70.TCG LIFE SCIENCE PVT. LTD.: NET SALES ($MILLION)